Home › Research › Topics › cognitive-impairment
cognitive-impairment
847 studies tagged cognitive-impairment, dated 1982-05-01 to 2026-09-16. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Feasibility of remote self-administered cognitive assessment in an Alzheimer's disease treatment clinic 2026-09-16
- Structural brain imaging for newly diagnosed cognitive impairment by Medicare coverage type 2026-09-15
- Detection and Continuous Monitoring of Memory Dysfunction in Mild Cognitive Impairment and Healthy Aging Through Adaptive Computational Phenotyping 2026-09-12
Studies
847 studies carry this tag.
Date range
1982 to 2026
Top journals
- Neurology 63
- Journal of Alzheimer's disease : JAD 31
- Archives of neurology 30
- Alzheimer s & Dementia 25
- Alzheimer's & dementia : the journal of the Alzheimer's Association 21
315 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
IntroductionRemote cognitive assessments offer an accessible, scalable way to support clinical characterization and longitudinal monitoring of cognition.
-
Structural brain imaging is guideline-recommended for cases with newly diagnosed cognitive impairment.
-
These findings show that model-based, adaptive assessments can support high-frequency, remote detection and scalable longitudinal monitoring of early memory decline, providing a new way to assess memory decline trajectories in healthy aging and dementia.
-
BackgroundDeep-learning models predict mild cognitive impairment (MCI)-to-Alzheimers disease (AD) conversion from structural MRI with high accuracy.
-
The Middle East and North Africa (MENA) region is projected to experience the fastest growth in dementia burden globally, yet population-based data on cognitive aging remain scarce.
-
BackgroundAccurate prediction of progression from mild cognitive impairment (MCI) to Alzheimers disease (AD) is important for prognosis, patient management, and clinical trial enrollment.
-
INTRODUCTIONMultimodal biomarkers have transformed Alzheimers disease research, but the incremental contribution of each modality to predicting progression from mild cognitive impairment (MCI) remains unclear.
-
Early identification of cognitive impairment remains challenging in settings where comprehensive cognitive and clinical assessments are not available.
-
The feasibility criteria of >80% was met.
-
46/100
Alzheimer's disease (AD) develops over a prolonged asymptomatic phase marked by silent pathology.
-
Non-White race and adverse social and socioeconomic factors-lower education, unemployment, unmarried status, and greater neighborhood disadvantage-were each associated with poorer cognitive performance (p < 0.05).
-
Mild cognitive impairment (MCI) is a stage between normal cognition and dementia, and timely diagnosis of this condition offers the opportunity for effective interventions to slow down the progression to dementia.
-
Eighty patients were included (mean age: 81 years, interquartile range 74-86 years; 36.2% female, ∼80% with dementia and Alzheimer disease).
-
baseline age = 79.6 years, 60.6% female.
-
The MMSE–CDR‐SB residual may help flag less AD‐typical presentations for further etiologic evaluation, but cannot be interpreted as a pathology‐specific marker due to substantial overlap across diagnostic groups.
-
36/100
There are significant opportunities for speech-language pathologists (SLPs) to play important roles in the primary and secondary prevention of Alzheimer's disease and related dementias (ADRD) beyond current practices.
-
Accurate prediction of the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is essential for early intervention and effective disease management.
-
Multicomponent and transdisciplinary interventions focused on the family member–patient dyad have the potential to optimize cognitive outcomes and quality of life.
-
Event-related potentials (ERPs), particularly the P300 component, provide a noninvasive, cost-effective approach to probing neural dysfunction in Alzheimer's disease (AD) and mild cognitive impairment (MCI).
-
In MCI and dementia, the HTS is an ecologically valid non-canonical sign, frequently occurs in daily life too, associated with longer disease duration and spatial disorientation.
-
Accurate detection of Mild Cognitive Impairment (MCI) is critical for timely intervention and for slowing progression to Alzheimer's disease.
-
EEG/ERP analysis suggested differences in frontal alpha asymmetry, power ratio, and ERP components between the MCI and CN groups.
-
SB-C significantly differentiated cognitively unimpaired and impaired groups (P < 0.001), correlated with standard cognitive measures, and showed moderate-to-high area under the curve (0.56-0.82) for classifying biomarker positivity, with strongest results in BioFINDER-Primary Care.
-
This study provides validated conversion tables between the Q mci screen and two widely-used cognitive instruments, to support the use of the Q mci screen in research (facilitating cross-instrument comparability and harmonization across studies), and clinical settings (determining eligibility for disease-modifying therapies).
-
Among 80 participants (mean [SD] age, lithium: 72.93 [8.77] years; placebo: 71.22 [6.47] years; 56% female), none of the 6 coprimary outcomes met the prespecified significance threshold.
-
Dementia developed in 104 individuals (29.6%), including 85 (22.4%) who met core clinical criteria for probable and possible Alzheimer's disease dementia.
-
SCD participants were older, had fewer years of education, more depressive symptoms, and more subjective cognitive complaints than CU participants.
-
Accurate prediction of progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is critical for early intervention.
-
BackgroundWhile transcranial alternating current stimulation (tACS) shows therapeutic promise for neurological and psychiatric disorders when applied repeatedly, its potential is constrained by multiple laboratory visits.
-
Integrating EEG features with plasma biomarkers improves prediction of cognitive function from mild cognitive impairment to moderate dementia, pending external validation.
-
Of 219 completing participants (mean age 73.5 years), the mean SUS score was 82.0 (95% CI: 80.3-83.8), with 84% exceeding the usability threshold (SUS score > 68).
-
The Level 3 model achieved high classification performance (AUC: 93.98%), and the Level 1 model achieved comparable performance (AUC: 91.53%).
-
The MMSE model achieves a mean absolute error (MAE) of 1.84 (95% CI: 1.64-2.04) internally and 2.19 in external validation.
-
Mild cognitive impairment (MCI) is an early stage in the progression toward dementia.
-
We observed measurement differences in the HCAP across H/L and NHW older adults for the memory, language, executive functioning, and orientation, but not visuospatial, domains.
-
BackgroundThe yes-no reversal (YNR) phenomenon consists in a patient saying "yes" when meaning "no", or vice-versa.
-
We developed a serum Raman spectroscopy-based ensemble learning approach for graded cognitive screening.
-
This study highlights the role of age, gender, APOE genotype, and depressive symptoms in the presentation and progression of cognitive decline.
-
MoCA scores showed significant positive correlations with cognitive-related cerebellar regions, particularly the left Crus I lobule (r = 0.40, p = 0.02) and total Crus I volume (r = 0.36, p = 0.04).
-
The prevalence of PIMcogs increased from 16% at baseline to 23% at follow-up.
-
Self- and informant-reported ADL and IADL impairments were examined at overall and item levels.
-
36/100
The psychometric properties of the Neuropsychiatry Unit Cognitive Assessment short-form versions were comparable with the original, with all maintaining high convergent validity and reliability.
-
Internal consistency of the ACE-III was strong (McDonald's ω = 0.889).
-
Parkinson's disease (PD) is a neurodegenerative condition that may affect both motor and cognitive function.
-
We found interactions between APOE4 and cognitive states in the aperiodic EEG exponent and the spectral power ratio (SPR).
-
Event-related potentials (ERPs), particularly the P200 component, have been studied as potential biomarkers, but conventional grand-averaged approaches often yield inconsistent results.
-
The model incorporating age, brain volume, functional, and radiomics features demonstrated the highest predictive performance for SCD progression in training (C-index: 0.962; 95 % CI: 0.95-0.98) and testing (C-index: 0.911; 95 % CI: 0.861-0.968) sets.
-
31/100
The model achieved and AUC of 0.72 [0.64, 0.81].
-
The development of non-pharmacological treatment approaches is supported by evidence that addressing key modifiable risk factors may prevent or delay up to 45% of dementia cases.
-
VARABOM.D scores showed significant positive associations with established cognitive assessments.
From across this tag
9 of the 846 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Midlife cognitive testing in Africa: validity of the Harmonised Cognitive Assessment Protocol in the Kenya Life Panel Survey
- Current concepts in mild cognitive impairment
- Mild cognitive impairment: an overview
- A Pilot Double-Blind Randomized Controlled Trial of Cognitive Training Combined with Transcranial Direct Current Stimulation for Amnestic Mild Cognitive Impairment
- Neuropsychological measures in normal individuals that predict subsequent cognitive decline
- Cognitive impairment and pain management: review of issues and challenges
- Progression of mild cognitive impairment to dementia due to AD in clinical settings
- Clinical and Biological Significance of Neuroinflammation Indicators to Predict the Course of Amnestic Mild Cognitive Impairment
- Conventional and neuropsychological criteria for mild cognitive impairment show similar prognostic value for dementia across 12 years in a non-clinical setting